Observational studyMultiple sclerosis (Houndmills, Basingstoke, England)2018
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Observational study in Multiple sclerosis (Houndmills, Basingstoke, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Crossroads of Neuroinflammation and Biomarkers in Multiple Sclerosis: A Systematic Review.Cells · 2026Pooled it
- Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer's disease and multiple sclerosis: a systematic review.Frontiers in immunology · 2023Pooled it
- Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.Scientific reports · 2023Trial
- Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Trial
- Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- Trial
- Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.Annals of neurology · 2026Article
- Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis.Journal of neurology · 2026Article
- Retinal Layer Thickness for Risk Stratification of Progression Independent of Relapse Activity in Relapsing-Remitting Multiple Sclerosis.Brain and behavior · 2026Observational
- Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial.Brain : a journal of neurology · 2026Article
- Baseline Neuroinflammation Stratifies TSPO-PET Response to Disease-Modifying Therapy in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Building Towards Initiation, Moderation, De-Escalation and Cessation of Disease-Modifying Treatments for Multiple Sclerosis in Greece: An Expert Panel Consensus Meeting.Brain sciences · 2026Article
- Detecting progressing events in multiple sclerosis clinics in real-time is possible: Yes.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Accelerometry-derived activity fragmentation as a predictor of brain atrophy and disability progression in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple Sclerosis.Neurology · 2026Article
- Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis.European journal of neurology · 2026Article
- Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.Journal of neurology · 2026Observational
- The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Observational
- Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple Sclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConfirmed Expanded Disability Status Scale (EDSS) progression occurring after a fixed-study entry baseline is a common measure of disability increase in relapsing-remitting multiple sclerosis (RRMS) studies but may not detect all disability progression events, especially those unrelated to overt relapses.
objectiveTo evaluate possible measures of disability progression unrelated to relapse using EDSS data over ≈5.5 years from the Tysabri
methodsTOP is an ongoing, prospective, open-label study in RRMS patients receiving intravenous 300 mg natalizumab every 4 weeks. Measures of increasing disability were assessed using as a reference either study baseline score or a "roving" system that resets the reference score after ⩾24- or ⩾48-week confirmation of a new score.
resultsThis analysis included 5562 patients. Approximately 70% more EDSS progression events unrelated to relapse and 50% more EDSS worsening events overall were detected with a roving reference score (cumulative probability: 17.6% and 29.7%, respectively) than with a fixed reference baseline score (cumulative probability: 10.1% and 20.3%, respectively).
conclusionIn this long-term observational RRMS dataset, a roving EDSS reference value was more efficient than a study baseline EDSS reference in detecting progression/worsening events unrelated to relapses and thus the transition to secondary progressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.